Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00938080
Other study ID # AG013-ODOM-101
Secondary ID RAC0810-942
Status Completed
Phase Phase 1
First received July 9, 2009
Last updated January 6, 2014
Start date September 2009
Est. completion date September 2012

Study information

Verified date January 2014
Source ActoGeniX N.V.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and severity of oral mucositis (OM) in subjects receiving induction chemotherapy for the treatment of head and neck cancer.


Description:

The purpose of this study is to investigate the safety and tolerability of AG013 in subjects who are at risk for oral mucositis (OM) and to assess clinical efficacy of AG013 in the reduction of signs and symptoms of OM in patients receiving induction chemotherapy for the treatment of their head and neck cancer.

AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.

The proposed Phase 1b clinical trial will enroll subjects with head and neck cancer who develop OM during their first cycle of treatment with induction chemotherapy. OM is a painful, common toxicity of many forms of drug and radiation therapy used for the treatment of cancer. Subjects with OM get soreness, irritation, and ulcers in the mouth and may have difficulties eating, drinking or swallowing as a result of their cancer treatment.

During the second cycle of induction chemotherapy, eligible subjects will receive AG013 or placebo for 14 consecutive days at a frequency of one rinse, three rinses or six rinses per day (sequential dose escalation design).

At least 21 subjects will be enrolled in the study. For each of the three daily dose levels, 5 subjects will be assigned to AG013 (n=5) and 2 subjects will be assigned to placebo (n=2).

Throughout the study, safety will be monitored by collecting and recording Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood.

An independent Data Safety Monitoring Board (DSMB) will be constituted before the enrollment of subjects in order to review safety data from each enrollment group.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Willing and able to understand and sign the study specific Informed Consent Form (ICF) approved by the site's Institutional Review Board

- Males or females 18 years or older

- Recently diagnosed with pathologically-confirmed squamous cell carcinoma of the head and neck (e.g., oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, lips, sinuses, salivary glands, unknown primary)

- Planned to receive at least two cycles of induction chemotherapy of the same regimen consisting of cisplatin/fluorouracil (PF) or cisplatin/fluorouracil/docetaxel (PFT). The planned CT cycles must be of the same length and must be a minimum of 14 days in length

- Karnofsky performance score = 60%

- Screening laboratory assessments:

- Hemoglobin = 10g/dl

- White blood count = 3500 cells/mm3

- Absolute neutrophil counts = 1500 cells/ mm3

- Direct bilirubin = 2x upper limit of normal (ULN)

- Serum AST and ALT = 3 x ULN

- Serum creatinine = 2 mg/dl

- Serum pregnancy test: negative for females of childbearing potential: A women is considered to be of child bearing potential unless she has had a tubal ligation or is postmenopausal (without a menstrual period for at least one year)

- Subjects of childbearing potential must agree to utilize effective contraceptive methods of birth control during study participation and for 30 days following the last treatment with IMP

- Have documented mouth pain during CT Cycle 1 (i.e., OMDQ question 2 score of = 2 during CT Cycle 1)

Exclusion Criteria:

- Prior radiation to the head and neck

- Chemotherapy within 21 days prior to study start

- Presence of active infectious disease excluding oral candidiasis

- Current use of antibiotic rinses or troches

- Alcohol abuse syndrome; recovered alcoholics may be included

- Presence of OM (WHO Grade > 0)

- Chronic immunosuppression

- Known seropositive for HIV or hepatitis B or C

- Use of investigational agent within 30 days of signing informed consent

- Teeth extractions within 7 days prior to the start of CT administration

- Female subjects who are pregnant or nursing

- Known sensitivity to any investigational agent

- Inability to give informed consent or comply with study requirements

- Unwilling or unable to complete subject diary

- Any other clinical condition, psychiatric condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable or to comply with follow-up visits

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)


Intervention

Biological:
AG013
Mouth rinse once a day for 14 days
AG013
Mouth rinse three times a day for 14 days
AG013
Mouth rinse six times a day for 14 days
Other:
Placebo
Mouth rinse once a day for 14 days
Placebo
Mouth rinse three times a day for 14 days
Placebo
Mouth rinse six times a day for 14 days

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts
United States Carolinas Medical Center Charlotte North Carolina
United States University of Illinois at Chicago Chicago Illinois
United States Vanderbilt Ingram Cancer Center Nashville Tennessee
United States Beth Israel Medical Center New York New York
United States Stanford University Stanford California

Sponsors (1)

Lead Sponsor Collaborator
ActoGeniX N.V.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety (Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood) Up to 16 months 16 months Yes
Secondary Pharmacokinetics of serum samples, buccal smears and saliva samples Day 1 CT cycle 2, Day 7 CT cycle 2, Day 14 CT cycle 2, End of Study 28 days No
See also
  Status Clinical Trial Phase
Completed NCT02229136 - Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus Phase 2
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Enrolling by invitation NCT02662374 - Oral Hygiene Regimen in Patients on HCT Phase 4
Completed NCT00756951 - Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer Phase 2
Completed NCT00701688 - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Not yet recruiting NCT05059613 - Thalidomide With or Without Probiotics in Radioactive Oral Mucositis N/A
Completed NCT04440930 - White Tea for Prevention of Chemotherapy Induced Mucositis N/A
Completed NCT05705622 - The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients N/A
Completed NCT02399228 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis Phase 2
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Enrolling by invitation NCT06122636 - Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC N/A
Completed NCT03689712 - ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients Phase 3
Terminated NCT02539342 - Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy Phase 3
Completed NCT02555501 - Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy Phase 3
Completed NCT01789658 - Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation N/A
Completed NCT00790322 - Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy Phase 3
Recruiting NCT00549952 - Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients N/A
Completed NCT00289003 - The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients Phase 2
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A

External Links